Answers are grounded in this paper and cite their sources.
Background : Oral antiviral agents, such as besifovir (BSV) and tenofovir alafenamide (TAF), are first-line treatments for chronic hepatitis B. Approved by the Ministry of Food and Drug Safety (MFDS) in 2017, these medications require long-term use due to challenges of achieving a 'sterilizing cure'.This study evaluated their long-term efficacy and safety in treatment-nave patients.Methods : This retrospective study reviewed medical records of patients aged 18 years or older who initiated treatment with BSV or TAF at a single institution between November 2017 and December 2023.Cumulative virological response (VR), changes in liver fibrosis and steatosis, and adverse effects, including renal impairment and hypercholesterolemia were compared between the two groups.Results : Among 603 patients, 187 were in the BSV group, and 416 in the TAF group.The BSV group demonstrated a significantly (p<0.05)higher cumulative VR rate (HBV DNA <10 IU/mL) than the TAF group, while TAF was associated with a higher cumulative VR60 rate (HBV DNA <60 IU/mL, p<0.05).The BSV group also showed significantly (p<0.05)greater improvements in liver fibrosis and steatosis.However, safety outcomes showed no significant differences between the two groups over the study period. Conclusion :This study confirmed that BSV achieved higher VR and greater improvements in liver fibrosis
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: